Nuvectis Pharma, Inc.
HealthcareNASDAQ:NVCT · NASDAQ Capital Market
+$0.20 today
Vol 0.07M · Avg 0.08M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-143.6%
avg -73.1%
ROIC
-149.8%
avg -146.9%
ROA
-83.4%
avg -98.1%
Analysis
ROA is currently the strongest return metric at -83.4% versus its period average of -98.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Ron Bentsur | Co-Founder, Chairman, Chief Executive Officer & President | $1.19M | — | 60 | $3.68M | 13.86% |
Shay Shemesh | Co-Founder, Executive Vice President, Chief Development & Operations Officer | $749,241.00 | — | 42 | $1.79M | 6.76% |
Enrique Poradosu | Co-Founder, Executive Vice President, Chief Scientific & Business Officer | $749,241.00 | — | 59 | $1.81M | 6.81% |
Michael Carson | Vice President of Finance | — | — | 50 | $200,118.00 | 0.75% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
9
$1.44M
Sells
0
$0.00
Net Sentiment
+$1.44M
Net buying
Most Active
Mosseri Marlio Charles
6 transactions
Analysis
Insiders reported 9 buys worth $1.44M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $1.44M. Mosseri Marlio Charles was the most active insider with 6 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Cybin Inc.
CYBN
$413.02M
Armata Pharmaceuticals, Inc.
AMEX:ARMP
$278.27M
Compugen Ltd.
NASDAQ:CGEN
$192.89M
Tonix Pharmaceuticals Holding Corp.
NASDAQ:TNXP
$180.93M
Innate Pharma S.A.
NASDAQ:IPHA
$165.27M
Molecular Partners AG
NASDAQ:MOLN
$154.17M
Milestone Pharmaceuticals Inc.
NASDAQ:MIST
$109.08M
Cardiff Oncology, Inc.
NASDAQ:CRDF
$105.29M
Cassava Sciences, Inc.
SAVA
$63.77M
Rani Therapeutics Holdings, Inc.
NASDAQ:RANI
$49.65M
Who manages NVCT?
Nuvectis Pharma, Inc. (NVCT) lists 4 active executives. The top listed executive is Ron Bentsur, Co-Founder, Chairman, Chief Executive Officer & President.
Are NVCT insiders buying or selling?
Recent insider activity shows net buying of $9.95M.
Explore More
Continue the stock analysis
Jump to another research area for this company.